| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Typhoid Fever | 44 | 2023 | 46 | 11.490 |
Why?
|
| Disease Outbreaks | 53 | 2024 | 169 | 9.300 |
Why?
|
| Cholera | 41 | 2024 | 73 | 9.140 |
Why?
|
| Diarrhea | 47 | 2023 | 95 | 6.830 |
Why?
|
| Salmonella typhi | 31 | 2023 | 33 | 6.250 |
Why?
|
| Sanitation | 20 | 2023 | 27 | 3.790 |
Why?
|
| Water Supply | 23 | 2023 | 59 | 3.270 |
Why?
|
| Typhoid-Paratyphoid Vaccines | 11 | 2020 | 11 | 2.940 |
Why?
|
| Child, Preschool | 77 | 2024 | 1516 | 2.770 |
Why?
|
| Travel | 15 | 2021 | 34 | 2.330 |
Why?
|
| Anti-Bacterial Agents | 26 | 2023 | 415 | 2.290 |
Why?
|
| Infant | 62 | 2024 | 1143 | 2.210 |
Why?
|
| Feces | 24 | 2023 | 126 | 2.000 |
Why?
|
| Cholera Vaccines | 10 | 2023 | 18 | 1.840 |
Why?
|
| Water Purification | 10 | 2020 | 33 | 1.810 |
Why?
|
| Child | 60 | 2024 | 3381 | 1.680 |
Why?
|
| Salmonella Infections | 7 | 2021 | 16 | 1.660 |
Why?
|
| Dysentery, Bacillary | 11 | 2015 | 13 | 1.640 |
Why?
|
| Vibrio cholerae O1 | 6 | 2018 | 11 | 1.610 |
Why?
|
| Humans | 159 | 2024 | 42163 | 1.580 |
Why?
|
| Case-Control Studies | 36 | 2023 | 1266 | 1.460 |
Why?
|
| Paratyphoid Fever | 7 | 2018 | 7 | 1.440 |
Why?
|
| Water Microbiology | 14 | 2020 | 82 | 1.370 |
Why?
|
| Kenya | 29 | 2023 | 56 | 1.320 |
Why?
|
| Hygiene | 8 | 2020 | 13 | 1.310 |
Why?
|
| Drug Resistance, Bacterial | 9 | 2016 | 88 | 1.260 |
Why?
|
| Population Surveillance | 17 | 2018 | 245 | 1.210 |
Why?
|
| Escherichia coli Infections | 8 | 2023 | 43 | 1.210 |
Why?
|
| Endemic Diseases | 3 | 2016 | 22 | 1.200 |
Why?
|
| Female | 87 | 2024 | 24018 | 1.140 |
Why?
|
| Vaccination | 7 | 2015 | 332 | 1.130 |
Why?
|
| Adolescent | 52 | 2024 | 5950 | 1.120 |
Why?
|
| Male | 86 | 2024 | 22779 | 1.110 |
Why?
|
| Adult | 64 | 2024 | 13458 | 1.010 |
Why?
|
| Middle Aged | 54 | 2024 | 11819 | 0.910 |
Why?
|
| Young Adult | 34 | 2024 | 4936 | 0.880 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 7 | 2020 | 34 | 0.870 |
Why?
|
| Cryptosporidiosis | 6 | 2023 | 6 | 0.860 |
Why?
|
| Ceftriaxone | 2 | 2021 | 7 | 0.850 |
Why?
|
| Incidence | 22 | 2024 | 1054 | 0.840 |
Why?
|
| Fever | 4 | 2021 | 63 | 0.840 |
Why?
|
| Salmonella | 2 | 2021 | 12 | 0.840 |
Why?
|
| Microbial Sensitivity Tests | 16 | 2022 | 232 | 0.820 |
Why?
|
| Risk Factors | 28 | 2023 | 3942 | 0.810 |
Why?
|
| Aged | 37 | 2024 | 7982 | 0.790 |
Why?
|
| Family Characteristics | 8 | 2018 | 124 | 0.790 |
Why?
|
| Aged, 80 and over | 22 | 2020 | 2803 | 0.780 |
Why?
|
| Food Microbiology | 11 | 2020 | 38 | 0.780 |
Why?
|
| Infant, Newborn | 23 | 2023 | 960 | 0.780 |
Why?
|
| Shigella | 6 | 2021 | 10 | 0.760 |
Why?
|
| Foodborne Diseases | 6 | 2014 | 24 | 0.740 |
Why?
|
| Haiti | 14 | 2024 | 86 | 0.740 |
Why?
|
| Rural Population | 13 | 2018 | 352 | 0.720 |
Why?
|
| Drug Resistance, Microbial | 2 | 2020 | 26 | 0.690 |
Why?
|
| United States | 27 | 2021 | 5072 | 0.670 |
Why?
|
| Escherichia coli | 11 | 2021 | 461 | 0.670 |
Why?
|
| Sepsis | 1 | 2021 | 90 | 0.650 |
Why?
|
| Rotavirus Infections | 6 | 2023 | 17 | 0.630 |
Why?
|
| Vibrio cholerae | 8 | 2024 | 103 | 0.600 |
Why?
|
| Uganda | 7 | 2021 | 22 | 0.590 |
Why?
|
| Communicable Disease Control | 3 | 2013 | 38 | 0.580 |
Why?
|
| Funeral Rites | 1 | 2018 | 1 | 0.580 |
Why?
|
| Cryptosporidium | 4 | 2023 | 4 | 0.570 |
Why?
|
| Financing, Personal | 1 | 2017 | 9 | 0.560 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 9 | 2014 | 27 | 0.540 |
Why?
|
| Health Expenditures | 1 | 2017 | 44 | 0.540 |
Why?
|
| Disinfection | 3 | 2007 | 10 | 0.520 |
Why?
|
| Disease Transmission, Infectious | 3 | 2013 | 30 | 0.510 |
Why?
|
| Enteritis | 1 | 2016 | 6 | 0.500 |
Why?
|
| Cholera Toxin | 2 | 2008 | 41 | 0.490 |
Why?
|
| Cost of Illness | 6 | 2016 | 95 | 0.480 |
Why?
|
| Time Factors | 12 | 2020 | 1848 | 0.480 |
Why?
|
| Africa | 9 | 2019 | 81 | 0.480 |
Why?
|
| Urban Health | 1 | 2016 | 99 | 0.470 |
Why?
|
| World Health Organization | 7 | 2015 | 36 | 0.470 |
Why?
|
| Developing Countries | 9 | 2019 | 112 | 0.460 |
Why?
|
| Shigella flexneri | 4 | 2015 | 6 | 0.460 |
Why?
|
| Malawi | 4 | 2018 | 10 | 0.450 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 309 | 0.450 |
Why?
|
| Laboratories | 4 | 2022 | 40 | 0.440 |
Why?
|
| Topography, Medical | 1 | 2014 | 2 | 0.430 |
Why?
|
| Logistic Models | 10 | 2020 | 1001 | 0.420 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2013 | 6 | 0.420 |
Why?
|
| Africa South of the Sahara | 10 | 2019 | 51 | 0.420 |
Why?
|
| Cluster Analysis | 5 | 2019 | 206 | 0.420 |
Why?
|
| Food Contamination | 4 | 2017 | 55 | 0.410 |
Why?
|
| Pakistan | 3 | 2022 | 20 | 0.400 |
Why?
|
| Shigella sonnei | 4 | 2009 | 5 | 0.400 |
Why?
|
| Nervous System | 1 | 2012 | 33 | 0.390 |
Why?
|
| Child Mortality | 1 | 2012 | 11 | 0.380 |
Why?
|
| Disasters | 4 | 2014 | 74 | 0.380 |
Why?
|
| Hospitalization | 6 | 2016 | 482 | 0.380 |
Why?
|
| Doxycycline | 1 | 2012 | 32 | 0.380 |
Why?
|
| Leptospira | 1 | 2012 | 27 | 0.380 |
Why?
|
| Intestinal Perforation | 1 | 2012 | 11 | 0.370 |
Why?
|
| Vaccines | 2 | 2023 | 64 | 0.370 |
Why?
|
| Leptospirosis | 1 | 2012 | 30 | 0.370 |
Why?
|
| Immunization Programs | 4 | 2017 | 24 | 0.370 |
Why?
|
| Sensitivity and Specificity | 8 | 2015 | 602 | 0.370 |
Why?
|
| Zimbabwe | 4 | 2019 | 5 | 0.360 |
Why?
|
| Halogenation | 1 | 2011 | 19 | 0.350 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 76 | 0.350 |
Why?
|
| Health Personnel | 1 | 2013 | 262 | 0.350 |
Why?
|
| Bacteremia | 4 | 2019 | 37 | 0.340 |
Why?
|
| Fishes | 1 | 2011 | 59 | 0.340 |
Why?
|
| Diagnostic Tests, Routine | 3 | 2015 | 51 | 0.340 |
Why?
|
| Odds Ratio | 11 | 2020 | 587 | 0.330 |
Why?
|
| Fluid Therapy | 6 | 2013 | 29 | 0.330 |
Why?
|
| Soaps | 3 | 2020 | 3 | 0.330 |
Why?
|
| Anti-Infective Agents | 3 | 2012 | 74 | 0.330 |
Why?
|
| Chlorine | 6 | 2020 | 10 | 0.320 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 708 | 0.310 |
Why?
|
| Health Knowledge, Attitudes, Practice | 6 | 2018 | 959 | 0.300 |
Why?
|
| Norovirus | 5 | 2023 | 15 | 0.300 |
Why?
|
| Vibrio cholerae non-O1 | 1 | 2008 | 2 | 0.300 |
Why?
|
| Ciprofloxacin | 4 | 2023 | 16 | 0.280 |
Why?
|
| Rotavirus | 4 | 2023 | 14 | 0.280 |
Why?
|
| Shigella dysenteriae | 1 | 2007 | 1 | 0.270 |
Why?
|
| Shiga Toxin 1 | 1 | 2007 | 3 | 0.270 |
Why?
|
| Restaurants | 6 | 2008 | 39 | 0.270 |
Why?
|
| Urban Population | 5 | 2020 | 364 | 0.270 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 471 | 0.270 |
Why?
|
| Age Distribution | 5 | 2013 | 249 | 0.260 |
Why?
|
| Salmonella paratyphi A | 4 | 2018 | 4 | 0.260 |
Why?
|
| Equipment Contamination | 1 | 2006 | 6 | 0.250 |
Why?
|
| Asia | 5 | 2019 | 99 | 0.250 |
Why?
|
| Disaster Planning | 1 | 2007 | 58 | 0.250 |
Why?
|
| Serotyping | 6 | 2014 | 37 | 0.240 |
Why?
|
| Metals | 1 | 2006 | 113 | 0.230 |
Why?
|
| Diarrhea, Infantile | 3 | 2013 | 5 | 0.230 |
Why?
|
| Cattle | 2 | 2023 | 505 | 0.230 |
Why?
|
| Dysentery | 2 | 2019 | 2 | 0.220 |
Why?
|
| Enterotoxigenic Escherichia coli | 2 | 2019 | 5 | 0.220 |
Why?
|
| Clinical Competence | 1 | 2006 | 154 | 0.220 |
Why?
|
| Sentinel Surveillance | 2 | 2015 | 24 | 0.220 |
Why?
|
| Rotavirus Vaccines | 2 | 2023 | 14 | 0.220 |
Why?
|
| Fresh Water | 1 | 2004 | 48 | 0.210 |
Why?
|
| Animals | 15 | 2023 | 16695 | 0.210 |
Why?
|
| Serologic Tests | 1 | 2004 | 45 | 0.210 |
Why?
|
| Health Education | 4 | 2020 | 358 | 0.210 |
Why?
|
| Antibodies, Bacterial | 4 | 2024 | 117 | 0.210 |
Why?
|
| Administration, Oral | 4 | 2017 | 256 | 0.210 |
Why?
|
| HIV Infections | 6 | 2018 | 2535 | 0.200 |
Why?
|
| Enteropathogenic Escherichia coli | 1 | 2023 | 3 | 0.200 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2023 | 5 | 0.200 |
Why?
|
| Ethiopia | 1 | 2023 | 15 | 0.200 |
Why?
|
| Shellfish | 2 | 2014 | 14 | 0.200 |
Why?
|
| Bacteria | 1 | 2006 | 285 | 0.200 |
Why?
|
| Mozambique | 2 | 2012 | 3 | 0.190 |
Why?
|
| Quinolones | 1 | 2022 | 13 | 0.190 |
Why?
|
| Enterobacteriaceae | 3 | 2013 | 29 | 0.190 |
Why?
|
| Growth Disorders | 1 | 2021 | 23 | 0.180 |
Why?
|
| Salmonella enterica | 3 | 2015 | 9 | 0.180 |
Why?
|
| Gastroenteritis | 3 | 2007 | 18 | 0.180 |
Why?
|
| Child, Hospitalized | 1 | 2021 | 1 | 0.180 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2003 | 172 | 0.180 |
Why?
|
| Public Health | 5 | 2018 | 405 | 0.170 |
Why?
|
| Bacterial Infections | 3 | 2013 | 44 | 0.170 |
Why?
|
| Guinea-Bissau | 2 | 2011 | 2 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 5 | 2019 | 454 | 0.170 |
Why?
|
| Iraq | 1 | 2020 | 8 | 0.170 |
Why?
|
| Zambia | 4 | 2020 | 47 | 0.160 |
Why?
|
| Communicable Diseases | 2 | 2018 | 47 | 0.160 |
Why?
|
| Prevalence | 7 | 2019 | 1597 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2020 | 82 | 0.160 |
Why?
|
| Filtration | 2 | 2018 | 17 | 0.160 |
Why?
|
| Dominican Republic | 2 | 2011 | 20 | 0.160 |
Why?
|
| Glass | 2 | 2009 | 19 | 0.160 |
Why?
|
| Carrier State | 1 | 2019 | 33 | 0.160 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 176 | 0.150 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2009 | 44 | 0.150 |
Why?
|
| Silver | 2 | 2009 | 61 | 0.150 |
Why?
|
| Fimbriae Proteins | 1 | 2019 | 21 | 0.150 |
Why?
|
| DNA, Bacterial | 3 | 2008 | 207 | 0.150 |
Why?
|
| Health Services Research | 1 | 2019 | 161 | 0.150 |
Why?
|
| Ceramics | 1 | 2018 | 6 | 0.140 |
Why?
|
| Security Measures | 1 | 2018 | 3 | 0.140 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 438 | 0.140 |
Why?
|
| Prospective Studies | 6 | 2019 | 1574 | 0.140 |
Why?
|
| Virulence Factors | 1 | 2019 | 119 | 0.140 |
Why?
|
| Animals, Domestic | 1 | 2017 | 11 | 0.140 |
Why?
|
| Toilet Facilities | 1 | 2017 | 3 | 0.140 |
Why?
|
| Homosexuality, Male | 1 | 2003 | 483 | 0.140 |
Why?
|
| Government Programs | 1 | 2017 | 29 | 0.140 |
Why?
|
| Costs and Cost Analysis | 1 | 2017 | 61 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 638 | 0.130 |
Why?
|
| Pain | 1 | 2020 | 283 | 0.130 |
Why?
|
| Refugees | 1 | 2017 | 21 | 0.130 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2017 | 7 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 3 | 2009 | 28 | 0.130 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2017 | 25 | 0.130 |
Why?
|
| Capacity Building | 1 | 2018 | 99 | 0.130 |
Why?
|
| Perception | 2 | 2017 | 209 | 0.130 |
Why?
|
| Quality of Health Care | 1 | 2017 | 158 | 0.130 |
Why?
|
| Blood | 2 | 2014 | 37 | 0.120 |
Why?
|
| Agglutination Tests | 2 | 2014 | 4 | 0.120 |
Why?
|
| Metal Nanoparticles | 2 | 2009 | 227 | 0.120 |
Why?
|
| Poverty | 1 | 2019 | 395 | 0.120 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2015 | 24 | 0.120 |
Why?
|
| Food Handling | 3 | 2012 | 35 | 0.120 |
Why?
|
| Immunoassay | 2 | 2016 | 69 | 0.120 |
Why?
|
| Seasons | 1 | 2016 | 133 | 0.120 |
Why?
|
| Polysaccharides, Bacterial | 2 | 2014 | 17 | 0.120 |
Why?
|
| Gastrointestinal Diseases | 1 | 2016 | 51 | 0.120 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 47 | 0.120 |
Why?
|
| Hospitals, Psychiatric | 1 | 2015 | 16 | 0.120 |
Why?
|
| Survival Rate | 2 | 2016 | 353 | 0.120 |
Why?
|
| Earthquakes | 2 | 2013 | 7 | 0.120 |
Why?
|
| Pregnancy Complications | 1 | 2016 | 134 | 0.110 |
Why?
|
| Cross Infection | 1 | 2015 | 47 | 0.110 |
Why?
|
| Inflammation | 1 | 2020 | 729 | 0.110 |
Why?
|
| Interviews as Topic | 2 | 2014 | 428 | 0.110 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 76 | 0.110 |
Why?
|
| Shigella Vaccines | 1 | 2014 | 1 | 0.110 |
Why?
|
| Area Under Curve | 1 | 2014 | 95 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2015 | 98 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2014 | 3077 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2017 | 362 | 0.110 |
Why?
|
| Caliciviridae Infections | 2 | 2004 | 8 | 0.110 |
Why?
|
| Infant Mortality | 1 | 2014 | 64 | 0.110 |
Why?
|
| Sanitary Engineering | 1 | 2013 | 2 | 0.110 |
Why?
|
| Brachyura | 1 | 2014 | 14 | 0.110 |
Why?
|
| Antigens, Bacterial | 2 | 2006 | 144 | 0.110 |
Why?
|
| Molecular Epidemiology | 2 | 2016 | 58 | 0.100 |
Why?
|
| Biosurveillance | 1 | 2013 | 1 | 0.100 |
Why?
|
| Drug Discovery | 1 | 2014 | 106 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2012 | 18 | 0.100 |
Why?
|
| Cyclonic Storms | 1 | 2014 | 75 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2012 | 61 | 0.100 |
Why?
|
| Guyana | 1 | 2012 | 1 | 0.100 |
Why?
|
| Floods | 1 | 2012 | 6 | 0.100 |
Why?
|
| Vibrio mimicus | 1 | 2012 | 1 | 0.100 |
Why?
|
| Vibrio Infections | 1 | 2012 | 4 | 0.100 |
Why?
|
| Astacoidea | 1 | 2012 | 3 | 0.090 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2012 | 12 | 0.090 |
Why?
|
| Seroepidemiologic Studies | 3 | 2024 | 71 | 0.090 |
Why?
|
| Mammea | 1 | 2012 | 1 | 0.090 |
Why?
|
| Pregnancy | 2 | 2016 | 1737 | 0.090 |
Why?
|
| Guatemala | 4 | 2019 | 21 | 0.090 |
Why?
|
| Needs Assessment | 1 | 2013 | 180 | 0.090 |
Why?
|
| Drug Resistance, Multiple | 2 | 2017 | 28 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2013 | 362 | 0.090 |
Why?
|
| DNA Fingerprinting | 2 | 2008 | 17 | 0.090 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2011 | 385 | 0.090 |
Why?
|
| Genotype | 2 | 2019 | 796 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 87 | 0.090 |
Why?
|
| Health Policy | 1 | 2013 | 184 | 0.090 |
Why?
|
| Asia, Western | 3 | 2018 | 5 | 0.090 |
Why?
|
| Guam | 1 | 2011 | 83 | 0.090 |
Why?
|
| Environmental Monitoring | 3 | 2007 | 226 | 0.080 |
Why?
|
| Water | 2 | 2004 | 314 | 0.080 |
Why?
|
| Caregivers | 1 | 2013 | 195 | 0.080 |
Why?
|
| Fruit | 1 | 2012 | 178 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 225 | 0.080 |
Why?
|
| Ohio | 3 | 2007 | 17 | 0.080 |
Why?
|
| Housing | 2 | 2007 | 68 | 0.080 |
Why?
|
| Immunohistochemistry | 1 | 2012 | 928 | 0.080 |
Why?
|
| Enterotoxins | 2 | 2008 | 33 | 0.080 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2009 | 13 | 0.080 |
Why?
|
| Politics | 1 | 2009 | 42 | 0.080 |
Why?
|
| Mali | 2 | 2023 | 3 | 0.080 |
Why?
|
| History, 19th Century | 1 | 2009 | 26 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 577 | 0.080 |
Why?
|
| Southeastern United States | 1 | 2008 | 58 | 0.070 |
Why?
|
| Seafood | 1 | 2008 | 24 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2009 | 124 | 0.070 |
Why?
|
| Salmonella paratyphi C | 1 | 2008 | 1 | 0.070 |
Why?
|
| Salmonella paratyphi B | 1 | 2008 | 1 | 0.070 |
Why?
|
| Violence | 1 | 2009 | 133 | 0.070 |
Why?
|
| Child Day Care Centers | 2 | 2009 | 11 | 0.070 |
Why?
|
| Fluoroquinolones | 1 | 2008 | 8 | 0.070 |
Why?
|
| Case Management | 1 | 2008 | 24 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2008 | 97 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2008 | 1729 | 0.070 |
Why?
|
| Relief Work | 1 | 2007 | 7 | 0.070 |
Why?
|
| Water Pollutants | 1 | 2007 | 18 | 0.070 |
Why?
|
| Louisiana | 1 | 2007 | 49 | 0.070 |
Why?
|
| Eating | 2 | 2014 | 164 | 0.070 |
Why?
|
| Respiratory Tract Diseases | 1 | 2007 | 30 | 0.070 |
Why?
|
| Asia, Southeastern | 2 | 2018 | 12 | 0.060 |
Why?
|
| Confidence Intervals | 3 | 2014 | 162 | 0.060 |
Why?
|
| Humidity | 1 | 2006 | 12 | 0.060 |
Why?
|
| Hot Temperature | 1 | 2007 | 141 | 0.060 |
Why?
|
| Colony Count, Microbial | 1 | 2006 | 67 | 0.060 |
Why?
|
| Trimethoprim Resistance | 1 | 2006 | 1 | 0.060 |
Why?
|
| Ampicillin Resistance | 1 | 2006 | 3 | 0.060 |
Why?
|
| Ampicillin | 1 | 2006 | 7 | 0.060 |
Why?
|
| Illinois | 1 | 2005 | 11 | 0.060 |
Why?
|
| Chronic Disease | 2 | 2006 | 541 | 0.060 |
Why?
|
| Poliomyelitis | 2 | 2017 | 7 | 0.060 |
Why?
|
| Influenza in Birds | 2 | 2017 | 11 | 0.060 |
Why?
|
| New York | 1 | 2005 | 88 | 0.060 |
Why?
|
| India | 2 | 2016 | 105 | 0.060 |
Why?
|
| Mortality | 2 | 2019 | 174 | 0.060 |
Why?
|
| Hospitals | 2 | 2018 | 115 | 0.060 |
Why?
|
| Shigella boydii | 1 | 2004 | 1 | 0.050 |
Why?
|
| Mass Vaccination | 2 | 2016 | 7 | 0.050 |
Why?
|
| Birds | 2 | 2017 | 93 | 0.050 |
Why?
|
| Naval Medicine | 1 | 2004 | 3 | 0.050 |
Why?
|
| Texas | 1 | 2006 | 428 | 0.050 |
Why?
|
| Ships | 1 | 2004 | 9 | 0.050 |
Why?
|
| Beverages | 2 | 2017 | 65 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2024 | 121 | 0.050 |
Why?
|
| Vietnam | 1 | 2004 | 61 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2006 | 301 | 0.050 |
Why?
|
| Conservation of Natural Resources | 1 | 2004 | 49 | 0.050 |
Why?
|
| Hepatitis A | 1 | 2004 | 10 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 2485 | 0.050 |
Why?
|
| Kentucky | 1 | 2003 | 3 | 0.050 |
Why?
|
| Indiana | 1 | 2003 | 16 | 0.050 |
Why?
|
| Gambia | 1 | 2023 | 1 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 1804 | 0.050 |
Why?
|
| Petroselinum | 1 | 2003 | 4 | 0.050 |
Why?
|
| Public Health Practice | 2 | 2018 | 39 | 0.050 |
Why?
|
| Giardia | 1 | 2023 | 15 | 0.050 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2003 | 30 | 0.050 |
Why?
|
| Cough | 1 | 2023 | 20 | 0.050 |
Why?
|
| Helicobacter Infections | 1 | 2004 | 84 | 0.050 |
Why?
|
| Chloramphenicol | 1 | 2022 | 5 | 0.050 |
Why?
|
| Anthrax | 1 | 2002 | 18 | 0.050 |
Why?
|
| Bioterrorism | 1 | 2002 | 20 | 0.050 |
Why?
|
| International Cooperation | 1 | 2002 | 51 | 0.050 |
Why?
|
| Infant Food | 1 | 2002 | 12 | 0.050 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 680 | 0.050 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 1058 | 0.050 |
Why?
|
| Safety | 1 | 2002 | 51 | 0.050 |
Why?
|
| Demography | 1 | 2002 | 195 | 0.040 |
Why?
|
| Salmonella typhimurium | 1 | 2021 | 40 | 0.040 |
Why?
|
| Reproduction | 1 | 2002 | 92 | 0.040 |
Why?
|
| Nevada | 2 | 2012 | 5 | 0.040 |
Why?
|
| Genes, Immediate-Early | 1 | 2020 | 11 | 0.040 |
Why?
|
| Hyperalgesia | 1 | 2020 | 23 | 0.040 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 22 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 2 | 2009 | 158 | 0.040 |
Why?
|
| Bangladesh | 2 | 2010 | 26 | 0.040 |
Why?
|
| Health Surveys | 2 | 2013 | 401 | 0.040 |
Why?
|
| Chile | 1 | 2018 | 6 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2015 | 845 | 0.040 |
Why?
|
| Feeding Behavior | 1 | 2002 | 461 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 1221 | 0.030 |
Why?
|
| Yellow Fever | 1 | 2017 | 5 | 0.030 |
Why?
|
| Sheep, Domestic | 1 | 2017 | 8 | 0.030 |
Why?
|
| California | 2 | 2012 | 531 | 0.030 |
Why?
|
| Animal Husbandry | 1 | 2017 | 19 | 0.030 |
Why?
|
| Phylogeny | 1 | 2021 | 740 | 0.030 |
Why?
|
| Zoonoses | 1 | 2017 | 20 | 0.030 |
Why?
|
| Rodentia | 1 | 2017 | 47 | 0.030 |
Why?
|
| Research Design | 1 | 2019 | 370 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 69 | 0.030 |
Why?
|
| Hemorrhagic Fever, Ebola | 1 | 2017 | 31 | 0.030 |
Why?
|
| Plasminogen Inactivators | 1 | 2017 | 4 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2017 | 34 | 0.030 |
Why?
|
| Data Collection | 1 | 2018 | 210 | 0.030 |
Why?
|
| Water Pollution | 1 | 2017 | 13 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 1051 | 0.030 |
Why?
|
| Melanesia | 1 | 2016 | 22 | 0.030 |
Why?
|
| Suprachiasmatic Nucleus | 1 | 2017 | 44 | 0.030 |
Why?
|
| Gram-Negative Bacteria | 2 | 2009 | 27 | 0.030 |
Why?
|
| Vomiting | 1 | 2016 | 14 | 0.030 |
Why?
|
| Afghanistan | 1 | 2016 | 6 | 0.030 |
Why?
|
| Antigens, Viral | 1 | 2016 | 50 | 0.030 |
Why?
|
| Chickens | 1 | 2017 | 148 | 0.030 |
Why?
|
| Data Mining | 1 | 2016 | 30 | 0.030 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2017 | 81 | 0.030 |
Why?
|
| Parents | 1 | 2019 | 359 | 0.030 |
Why?
|
| Cryptosporidium parvum | 2 | 2007 | 3 | 0.030 |
Why?
|
| Environmental Exposure | 2 | 2012 | 247 | 0.030 |
Why?
|
| Diet | 1 | 2002 | 810 | 0.030 |
Why?
|
| Coronavirus Infections | 1 | 2017 | 81 | 0.030 |
Why?
|
| Cambodia | 1 | 2015 | 3 | 0.030 |
Why?
|
| Focus Groups | 1 | 2017 | 398 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2015 | 85 | 0.030 |
Why?
|
| American Samoa | 1 | 2015 | 18 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 97 | 0.030 |
Why?
|
| Health Resources | 1 | 2015 | 37 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 733 | 0.030 |
Why?
|
| Fiji | 1 | 2014 | 1 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2014 | 36 | 0.030 |
Why?
|
| Pacific Islands | 1 | 2014 | 121 | 0.030 |
Why?
|
| Sierra Leone | 1 | 2014 | 3 | 0.030 |
Why?
|
| Enterovirus A, Human | 1 | 2013 | 1 | 0.030 |
Why?
|
| Markov Chains | 1 | 2013 | 42 | 0.030 |
Why?
|
| Poliovirus | 1 | 2013 | 5 | 0.030 |
Why?
|
| Enterovirus Infections | 1 | 2013 | 4 | 0.030 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 1 | 2013 | 7 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2013 | 35 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 66 | 0.030 |
Why?
|
| Residence Characteristics | 1 | 2016 | 359 | 0.030 |
Why?
|
| Inpatients | 1 | 2013 | 78 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 456 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2013 | 76 | 0.020 |
Why?
|
| Washington | 1 | 2012 | 36 | 0.020 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 12 | 0.020 |
Why?
|
| Oregon | 1 | 2012 | 64 | 0.020 |
Why?
|
| Contact Tracing | 1 | 2012 | 22 | 0.020 |
Why?
|
| Emergencies | 1 | 2011 | 32 | 0.020 |
Why?
|
| Middle East | 1 | 2011 | 21 | 0.020 |
Why?
|
| DNA Topoisomerase IV | 1 | 2011 | 2 | 0.020 |
Why?
|
| Europe | 1 | 2011 | 114 | 0.020 |
Why?
|
| DNA Gyrase | 1 | 2011 | 7 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2013 | 336 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2013 | 206 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2015 | 377 | 0.020 |
Why?
|
| Malaria | 1 | 2012 | 90 | 0.020 |
Why?
|
| Botswana | 1 | 2010 | 5 | 0.020 |
Why?
|
| Infant Formula | 1 | 2010 | 17 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 599 | 0.020 |
Why?
|
| Photoelectron Spectroscopy | 1 | 2009 | 6 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2010 | 46 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 7 | 0.020 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2011 | 168 | 0.020 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 66 | 0.020 |
Why?
|
| Infection Control | 1 | 2009 | 17 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2009 | 160 | 0.020 |
Why?
|
| Breast Feeding | 1 | 2010 | 123 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2009 | 89 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2008 | 34 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 2008 | 50 | 0.020 |
Why?
|
| Nanotechnology | 1 | 2009 | 176 | 0.020 |
Why?
|
| Antimalarials | 1 | 2008 | 63 | 0.020 |
Why?
|
| Flocculation | 1 | 2007 | 6 | 0.020 |
Why?
|
| Disinfectants | 1 | 2007 | 8 | 0.020 |
Why?
|
| Malaria, Falciparum | 1 | 2008 | 91 | 0.020 |
Why?
|
| Giardia lamblia | 1 | 2007 | 32 | 0.020 |
Why?
|
| Plasmodium falciparum | 1 | 2008 | 146 | 0.020 |
Why?
|
| Campylobacter jejuni | 1 | 2007 | 22 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2008 | 133 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 107 | 0.020 |
Why?
|
| China | 1 | 2007 | 233 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2007 | 224 | 0.020 |
Why?
|
| O Antigens | 1 | 2006 | 7 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1169 | 0.020 |
Why?
|
| Tennessee | 1 | 2006 | 88 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 6490 | 0.010 |
Why?
|
| Schools | 1 | 2007 | 283 | 0.010 |
Why?
|
| Parasitic Diseases | 1 | 2004 | 6 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2005 | 229 | 0.010 |
Why?
|
| Virus Diseases | 1 | 2004 | 27 | 0.010 |
Why?
|
| Recreation | 1 | 2004 | 42 | 0.010 |
Why?
|
| Hepatitis A virus | 1 | 2004 | 2 | 0.010 |
Why?
|
| Hydrotherapy | 1 | 2003 | 1 | 0.010 |
Why?
|
| Viral Vaccines | 1 | 2004 | 36 | 0.010 |
Why?
|
| Acute Disease | 1 | 2004 | 156 | 0.010 |
Why?
|
| Micronesia | 1 | 2003 | 87 | 0.010 |
Why?
|
| Diapers, Infant | 1 | 2003 | 1 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2004 | 115 | 0.010 |
Why?
|
| HIV-1 | 1 | 2009 | 747 | 0.010 |
Why?
|
| Antibodies, Protozoan | 1 | 2004 | 82 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2008 | 1586 | 0.010 |
Why?
|
| Minnesota | 1 | 2003 | 41 | 0.010 |
Why?
|
| Culture Media | 1 | 2003 | 96 | 0.010 |
Why?
|
| Bacterial Vaccines | 1 | 2004 | 129 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2004 | 116 | 0.010 |
Why?
|
| Disease Notification | 1 | 2002 | 5 | 0.010 |
Why?
|
| Canada | 1 | 2003 | 157 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 649 | 0.010 |
Why?
|
| Bacillus anthracis | 1 | 2002 | 33 | 0.010 |
Why?
|
| Phodopus | 1 | 2002 | 3 | 0.010 |
Why?
|
| Survival | 1 | 2002 | 8 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2005 | 1020 | 0.010 |
Why?
|
| Litter Size | 1 | 2002 | 14 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 2002 | 35 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2002 | 34 | 0.010 |
Why?
|
| Lactation | 1 | 2002 | 44 | 0.010 |
Why?
|
| Occupational Exposure | 1 | 2002 | 89 | 0.010 |
Why?
|
| Organ Size | 1 | 2002 | 167 | 0.010 |
Why?
|
| Cricetinae | 1 | 2002 | 241 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2004 | 295 | 0.010 |
Why?
|
| Dietary Fats | 1 | 2002 | 117 | 0.010 |
Why?
|
| Energy Intake | 1 | 2002 | 162 | 0.010 |
Why?
|
| Body Composition | 1 | 2002 | 160 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2005 | 475 | 0.010 |
Why?
|
| Kinetics | 1 | 2002 | 698 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 180 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 428 | 0.010 |
Why?
|